AR059031A1 - Combinacion de derivados de triazina e inhibidores de la hmg- coa reductasa - Google Patents
Combinacion de derivados de triazina e inhibidores de la hmg- coa reductasaInfo
- Publication number
- AR059031A1 AR059031A1 ARP070100137A ARP070100137A AR059031A1 AR 059031 A1 AR059031 A1 AR 059031A1 AR P070100137 A ARP070100137 A AR P070100137A AR P070100137 A ARP070100137 A AR P070100137A AR 059031 A1 AR059031 A1 AR 059031A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkoxy
- alkyl
- aryl
- halogen
- optionally substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Reivindicacion 1: Composicion farmacéutica que comprende, como principio activo: i) un inhibidor de la HMG-CoA reductasa, ii) un derivado de la triazina de la formula (1) en donde: R1, R2, R3 y R4 se seleccionan en forma independiente entre los grupos siguientes: H; -alquilo C1-20 opcionalmente substituido con halogeno, alquilo C1-5, alcoxi C1-5, cicloalquilo C3-8; -alquenilo C2-20 opcionalmente substituido con halogeno, alquilo C1-5 o alcoxi C1-5; -alquinilo C2-20 opcionalmente substituido con halogeno, alquilo C1-5 o alcoxi C1-5; -cicloalquilo C3-8 opcionalmente substituido con alquilo C1-5 o alcoxi C1-5; -heterocicloalquilo C3-8 con uno o más heteroátomos seleccionados entre N, O y S y opcionalmente substituido con alquilo C1-5 o alcoxi C1-5; -aril C6-14alquilo C1-20 opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; -arilo C6-14 opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; -heteroarilo C1-13 con uno o más heteroátomos seleccionados entre N, O y S y opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; R1 y R2, por un lado, y R3 y R4, por otro lado, pueden formar con el átomo de nitrogeno un anillo de n-miembros (n es entre 3 y 8) que contiene opcionalmente uno o más heteroátomos seleccionados entre N, O y S y puede estar substituido por uno o más de los grupos siguientes: amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14-alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; R5 y R6 se seleccionan en forma independiente entre los grupos siguientes: -H; -alquilo C1-20 opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; -alquenilo C2-20 opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; -alquinilo C2-20 opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; -cicloalquilo C3-8 opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; -heterocicloalquilo C3-8 con uno o más heteroátomos seleccionados entre N, O y S y opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; -arilo C6-14 opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; heteroarilo C1-13 con uno o más heteroátomos seleccionados entre N, O y S y opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo; aril C6-14alquilo C1-5 opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo, R5 y R6 pueden formar con el átomo de carbono al cual están unidos un anillo de m miembros (m es entre 3 y 8) que contiene opcionalmente uno o más heteroátomos seleccionados entre N, O y S y pueden estar substituidos con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo, o pueden formar con el átomo de carbono un residuo policíclico C10-30 opcionalmente substituido con amino, hidroxilo, tio, halogeno, alquilo C1-5, alcoxi C1-5, alquiltio C1-5, alquilamino C1-5, ariloxi C6-14, aril C6-14alcoxi C1-5, ciano, trifluorometilo, carboxilo, carboximetilo o carboxietilo, R5 y R6 juntos pueden también representar grupo =O o =S, el átomo de nitrogeno de un grupo heterocicloalquilo o heteroarilo puede estar substituido con un grupo alquilo C1-5, cicloalquilo C3-8, arilo C6-14, aril C6-14alquilo C1-5 o acilo C1-6, y también las formas racémicas, tautomeras, enantiomeras, diastereoisomeros, epímeros y polimorfos, y mezclas de los mismos, y sus sales aceptables para uso farmacéutico, y uno o más excipientes aceptables para uso farmacéutico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0600343A FR2896158B1 (fr) | 2006-01-13 | 2006-01-13 | Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase. |
Publications (1)
Publication Number | Publication Date |
---|---|
AR059031A1 true AR059031A1 (es) | 2008-03-12 |
Family
ID=36649749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070100137A AR059031A1 (es) | 2006-01-13 | 2007-01-12 | Combinacion de derivados de triazina e inhibidores de la hmg- coa reductasa |
Country Status (14)
Country | Link |
---|---|
US (1) | US20100158999A1 (es) |
EP (1) | EP1978951A2 (es) |
JP (1) | JP2009523141A (es) |
KR (1) | KR20080085208A (es) |
CN (1) | CN101355935A (es) |
AR (1) | AR059031A1 (es) |
AU (1) | AU2006334733A1 (es) |
BR (1) | BRPI0621420A2 (es) |
CA (1) | CA2636840A1 (es) |
EA (1) | EA200801666A1 (es) |
FR (1) | FR2896158B1 (es) |
IL (1) | IL192594A0 (es) |
WO (1) | WO2007079916A2 (es) |
ZA (1) | ZA200806937B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
JP5320399B2 (ja) * | 2007-08-31 | 2013-10-23 | ハナル バイオファーマ カンパニーリミテッド | 1,3,5−トリアジン−2,4,6−トリアミン化合物またはその薬学的に許容可能な塩と、それを含む薬学組成物 |
EP2367802B1 (en) | 2008-12-12 | 2016-04-20 | Poxel | Tetrahydrotriazine compounds for treating diseases associated with ampk activity |
FR2948028B1 (fr) * | 2009-07-17 | 2011-12-02 | Merck Sante Sas | Association d'un inhibiteur de l'echangeur sodium-proton et d'un derive amine de dihydro-1,3,5-triazine |
EP2602249B1 (en) * | 2011-12-06 | 2015-08-12 | F.I.S. Fabbrica Italiana Sintetici S.p.A. | Synthesis of rosuvastatin by means of co-crystals |
MX2020013210A (es) | 2018-06-06 | 2021-02-26 | Metavant Sciences Gmbh | Metodos de tratamiento de sujetos que padecen diabetes con enfermedad renal cronica. |
EP3806828A1 (en) * | 2018-06-14 | 2021-04-21 | Poxel | Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes |
KR20220113942A (ko) * | 2019-12-13 | 2022-08-17 | 스미토모 파마 가부시키가이샤 | 제조성 및 용출성이 우수한 소형 정제 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3651816B2 (ja) * | 1995-07-03 | 2005-05-25 | 三共株式会社 | 動脈硬化症予防および治療剤 |
FR2804113B1 (fr) * | 2000-01-26 | 2004-06-18 | Lipha | Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique |
FR2853650B1 (fr) * | 2003-04-10 | 2006-07-07 | Merck Sante Sas | Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance |
EP1510208A1 (en) * | 2003-08-22 | 2005-03-02 | Fournier Laboratories Ireland Limited | Pharmaceutical composition comprising a combination of metformin and statin |
-
2006
- 2006-01-13 FR FR0600343A patent/FR2896158B1/fr not_active Expired - Fee Related
- 2006-12-18 EA EA200801666A patent/EA200801666A1/ru unknown
- 2006-12-18 CA CA002636840A patent/CA2636840A1/en not_active Abandoned
- 2006-12-18 CN CNA2006800508489A patent/CN101355935A/zh active Pending
- 2006-12-18 JP JP2008549782A patent/JP2009523141A/ja active Pending
- 2006-12-18 EP EP06829705A patent/EP1978951A2/en not_active Withdrawn
- 2006-12-18 WO PCT/EP2006/012184 patent/WO2007079916A2/en active Application Filing
- 2006-12-18 BR BRPI0621420-7A patent/BRPI0621420A2/pt not_active IP Right Cessation
- 2006-12-18 US US12/160,504 patent/US20100158999A1/en not_active Abandoned
- 2006-12-18 KR KR1020087019392A patent/KR20080085208A/ko not_active Application Discontinuation
- 2006-12-18 AU AU2006334733A patent/AU2006334733A1/en not_active Abandoned
-
2007
- 2007-01-12 AR ARP070100137A patent/AR059031A1/es unknown
-
2008
- 2008-07-02 IL IL192594A patent/IL192594A0/en unknown
- 2008-08-12 ZA ZA200806937A patent/ZA200806937B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP2009523141A (ja) | 2009-06-18 |
WO2007079916A3 (en) | 2007-12-06 |
EA200801666A1 (ru) | 2008-12-30 |
FR2896158B1 (fr) | 2008-09-12 |
BRPI0621420A2 (pt) | 2011-12-06 |
IL192594A0 (en) | 2009-09-22 |
CN101355935A (zh) | 2009-01-28 |
AU2006334733A1 (en) | 2007-07-19 |
KR20080085208A (ko) | 2008-09-23 |
FR2896158A1 (fr) | 2007-07-20 |
US20100158999A1 (en) | 2010-06-24 |
EP1978951A2 (en) | 2008-10-15 |
ZA200806937B (en) | 2009-07-29 |
CA2636840A1 (en) | 2007-07-19 |
WO2007079916A2 (en) | 2007-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR059032A1 (es) | Combinacion de derivados de triazina y sensibilizadores de insulina | |
AR059031A1 (es) | Combinacion de derivados de triazina e inhibidores de la hmg- coa reductasa | |
AR059030A1 (es) | Combinacion de derivados de triazina y estimuladores de la secrecion de insulina | |
AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
PE20200388A1 (es) | Amidas heterociclicas de 5 miembros y biciclicas como inhibidores de rock | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR076900A1 (es) | Derivados heterociclicos nitrogenados utiles como agentes antivirales, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del vhc | |
CR9980A (es) | Imidazolinas 4,4,5,5 tetrasustituidas | |
AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
GT200600134A (es) | Compuestos novedosos de derivados de aminosulfonilo | |
EA200702080A1 (ru) | Полициклическое карбомоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич | |
DK1753723T3 (da) | Substituerede quinolinderivater som mitotiske kinesininhibitorer | |
AR060807A1 (es) | Derivados de arilaminopiridina heteroaril - susutituidos como inhibidores de mek | |
PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
AR044078A1 (es) | Dihidroquinazolinas sustituidas | |
AR054481A1 (es) | Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol | |
AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
AR058885A1 (es) | Compuestos de piperidina 3,5-sustituidos | |
ECSP109958A (es) | Derivados de pirimidina 934 | |
AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
AR074053A1 (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y composiciones farmaceuticas que los contienen | |
AR078461A1 (es) | Inhibidores macrociclicos de la replicacion de virus de la hepatitis c | |
AR077534A1 (es) | Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |